logo
logo
Medpace Holdings, Inc.

Medpace Holdings, Inc.

NASDAQ•MEDP
CEO: Dr. August James Troendle M.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2016-08-11
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
連絡先情報
5375 Medpace Way, Cincinnati, OH, 45227, United States
513-579-9911
www.medpace.com
時価総額
$12.56B
PER (TTM)
28.0
21.3
配当利回り
--
52週高値
$628.92
52週安値
$250.05
52週レンジ
52%
順位20Top 6.4%
6.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$708.45M+0.00%
直近4四半期の推移

EPS

$4.78+0.00%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Nine months revenue reached $1.82B USD, marking a strong 15.9% increase compared to prior year period.
Quarterly Net Income Rises Q3 Net Income was $111.1M USD, showing $14.7M USD improvement over Q3 2024 results.
Strong Operating Income Performance Nine months income from operations totaled $381.7M USD, reflecting 15.1% growth compared to the prior year period.
Backlog Conversion Potential Total backlog stands at $3.00B USD as of September 30, 2025, a 2.5% increase from last year.

リスク要因

Significant Share Repurchase Cash Use Nine months financing cash flow used $883.1M USD, primarily due to $917.4M USD in common stock repurchases.
Cash Balance Reduction Cash and cash equivalents decreased to $285.4M USD from $669.4M USD since year-end 2024.
Higher Income Tax Provision Income tax provision increased $14.9M USD for nine months, due to lower FDII tax benefits.
Decreased Interest Income Nine months net interest income dropped $8.1M USD to $9.1M USD, driven by lower cash balances.

見通し

Remaining Share Repurchase Authority Remaining authorization for share repurchases stands at $821.7M USD under the current Board approved program.
New Tax Disclosure Adoption Expect adoption of ASU 2023-09 regarding income tax disclosures in the fourth quarter of fiscal year 2025.
Credit Facility Expiration Date Unsecured Credit Facility remains undrawn as of September 30, 2025; facility is set to expire April 30, 2027.
Purchase Commitments Visibility Minimum purchase commitments for supplies total $18.0M USD, expiring at various times through 2029.

同業比較

売上高 (TTM)

Centene CorporationCNC
$194.78B
+19.4%
Fresenius Medical Care AGFMS
$21.68B
+2.1%
Tenet Healthcare CorporationTHC
$20.86B
-0.6%

粗利益率 (最新四半期)

Neurocrine Biosciences, Inc.NBIX
98.2%
-0.5pp
Smith & Nephew plcSNN
70.6%
+0.8pp
Illumina, Inc.ILMN
67.0%
-1.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
DGX$22.96B23.013.9%39.3%
WAT$19.47B30.328.5%0.0%
CNC$19.47B-2.9-27.7%22.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
8.2%
安定成長
4四半期純利益CAGR
5.6%
収益性の着実な向上
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年4月20日
|
EPS:$3.77
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-K - FY 2025

    会計期末: 2025年12月31日|提出日: 2026年2月10日|
    売上高: $2.53B+20.0%
    |
    EPS: $15.64+19.8%
    予想を上回る

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月23日|
    売上高: $659.90M+23.7%
    |
    EPS: $3.95+27.0%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月22日|
    売上高: $603.31M+14.2%
    |
    EPS: $3.16+10.9%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月22日|
    売上高: $558.57M+9.3%
    |
    EPS: $3.77+13.6%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月11日|
    売上高: $2.11B+11.8%
    |
    EPS: $13.06+42.0%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月22日|
    売上高: $533.32M+8.3%
    |
    EPS: $3.11+35.2%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月23日|
    売上高: $528.10M+14.6%
    |
    EPS: $2.85+42.5%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年4月23日|
    売上高: $511.04M+17.7%
    |
    EPS: $3.32+41.3%
    予想を上回る